Spotlight
Clinical
Events
CME
Partners
Subscribe
- COVID-19
- Biosimilars
- Cataract Therapeutics
- DME
- Gene Therapy
- Workplace
- Ptosis
- Optic Relief
- Imaging
- Geographic Atrophy
- AMD
- Presbyopia
- Ocular Surface Disease
- Practice Management
- Pediatrics
- Surgery
- Therapeutics
- Optometry
- Retina
- Cataract
- Pharmacy
- IOL
- Dry Eye
- Understanding Antibiotic Resistance
- Refractive
- Cornea
- Glaucoma
- OCT
- Ocular Allergy
- Clinical Diagnosis
- Technology
FDA approves Bausch & Lomb 100 Hz Zyoptix laser
Bausch & Lomb announces that the FDA has approved the 217z100 Zyoptix excimer laser. The 100 Hz laser operates at twice the speed of the company?s current system in both standard and custom treatment modes.
Bausch & Lomb announces that the FDA has approved the 217z100 Zyoptix excimer laser. The 100 Hz laser operates at twice the speed of the company's current system in both standard and custom treatment modes.
The laser - with its unique combination of beam diameters and laser speed - is expected to be commercially available in July, along with an upgrade path to allow current users to access the faster technology.
For more information, visit Bausch & Lomb at Booth 426.
Related Videos
Related Content
